Today's $GILD news about Magrolimab really reframes this decision about passing on Tizona. The Gilead-oncology-deal-to-scrap-heap pipeline remains strong.
Gilead will not buy Tizona Therapeutics, the pharma confirmed, after investing $300 million for the right to do so. Buying Tizona could've cost up to an additional $1.25 billion. https://t.co/sE176134Gt
@BiotechElmo@jesse_brodkin And to understand why, simply consider: Do YOU eat the exact same amount of food every single day? Do YOU eat the exact same amount of food every 12 hrs? Every 6 hrs? Every 3 hrs?
Yeah. And neither does a mouse.
@BiotechElmo@jesse_brodkin Wait, so they reported the "dose" as ppm in chow...??
That sound you hear is the collective heavy sigh of every chemist throughout time simultaneously crying and smashing their head against a table.
So, basically, they have no one dose.
And before this, I was doing scientific due diligence for biotech investing and before that I started a company in the immune and allergy space. Point is, careers post grad school aren't linear/straight. We don't all fit on the same line. Jobs are a series of dots you connect
PhD: synthesis/crystallization dynamics of structurally precise polymer thin films
Real job: Internal innovation/intrapreneur creating new digital health businesses within a large pharma
What transfers: Hypothesis driven thinking, failing repeatedly to get the one that works.
PhD folks: QT this and talk about how your grad school work compares to what youโre doing in your career post-PhD. The same or different or very different? What skills did you take with you from your PhD that were most important to your job today?
What also transfers: critically evaluating priorities, designing the most impactful experiment to discharge risk, structuring an experimental plan.
What doesn't: i have not been at the bench in a decade, literally all my synthetic skills (I can still run a column though!)
@BiotechElmo FDA has routinely a willingness to grant AA's on even speculative markers (at least the neuro division has; they kinda live for it, I see you NfL...).
So maybe that is the play. It is all about that AA and sales while a super long fracture study runs. Who cares about outcomes...